IRCT20200913048701N1CompletedPhase 3
Evaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection.
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •Patients between 40 and 60 years of age with new coronavirus infection 2019 who have been admitted to Firoozabadi Hospital.
Exclusion Criteria
- •Age over 60 years
- •Age under 40 years
- •No hospitalization
- •No infection with coronavirus 2019
Investigators
Similar Trials
Recruiting
Phase 2
Oral safety and efficacy of eucalypt sap resin in the management of recurrent vulvovaginal candidiasisAlternative and Complementary Medicine - Herbal remediesInfection - Other infectious diseasesRenal and Urogenital - Other renal and urogenital disordersrecurrent vulvovaginal candidiasisACTRN12624000204549Integria Healthcare (Australia) Pty Ltd.24
Not yet recruiting
Phase 3
The effect of emulsion on the Process of diabetic wound healingDiabetic Wound Healing.IRCT20160118026096N2Tehran University of Medical Sciences60
Not yet recruiting
Phase 3
The efficacy of eucalyptus essence inhalation in hospitalized patients with COVID-19IRCT20201127049507N1Ghoum University of Medical Sciences40
Completed
Phase 4
The evaluation of the efficacy and safety of oral fingolimod in relapsing remitting multiple sclerosismultiple sclerosis.Disseminated Multiple SclerosisIRCT201406018323N10Vice-chancellor for research, Kermanshah University of Medical Sciences60
Completed
Phase 1
Oral safety and tolerability of Eucalypt and Corymbia sap resins in healthy adults – A randomised controlled studyIrritable bowel syndrome - DAlternative and Complementary Medicine - Herbal remediesOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12623000280606Integria Healthcare (Australia) Pty Ltd.42